查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2007859

人工智慧臨床試驗平台市場預測至2034年—按平台類型、部署模式、技術、應用、最終用戶和地區分類的全球分析

AI Clinical Trial Platforms Market Forecasts to 2034 - Global Analysis By Platform Type, Deployment Mode, Technology, Application, End User and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球 AI 臨床試驗平台市場規模將達到 34 億美元，並在預測期內以 23.8% 的複合年成長率成長，到 2034 年將達到 188 億美元。

人工智慧臨床試驗平台是指利用機器學習、預測建模、自然語言處理和真實世界數據分析來最佳化藥品和醫療設備臨床試驗的設計、執行、監測和監管申報的軟體系統。這些平台可自動完成受試者招募和合格篩檢、自適應試驗通訊協定設計、安全訊號檢測、臨床實驗績效管理以及資料完整性檢驗。其主要功能包括與電子資料收集 (EDC) 系統整合、支援分散式臨床實驗、基於生物標記的患者分層以及生成新藥研究申請 (IND) 和新藥認證協議 (NDA) 申報所需的監管文件。

加速藥物研發並簡化研究對象的招募流程

人工智慧臨床試驗平台正在加速藥物創新週期，協助全球藥物研發管線更快完成藥物開發，並提高受試者招募效率。先進的機器學習演算法簡化了受試者識別、研究中心選擇和通訊協定最佳化流程，顯著縮短了臨床實驗週期。臨床試驗贊助者方正日益利用即時數據分析最佳化決策，提高臨床實驗成功率。自動化程度的提高最大限度地減少了人工干預和操作延遲。因此，人工智慧的整合正在變革臨床工作流程，在臨床實驗激烈的市場環境中提高效率，同時降低整體研發成本。

資料隱私和監管合規問題

由於GDPR和HIPAA等嚴格的法規結構，資料隱私合規的複雜性成為人工智慧臨床試驗平台市場的主要阻礙因素。跨司法管轄區管理敏感的患者資料會增加營運負擔和合規成本。資料保護法律的區域差異也使跨境臨床研究和資料共用更加複雜。此外，確保資料儲存安全、匿名化和知情同意管理需要複雜的基礎設施，這限制了可擴展性，並減緩了人工智慧驅動的臨床試驗解決方案在全球範圍內的普及。

利用預測分析提高測試設計的效率

人工智慧臨床試驗平台為簡化試驗設計開啟了新的可能性。這些平台能夠實現精準的患者分層、風險評估和結果預測，進而提高試驗的準確性。製藥公司正擴大採用人工智慧驅動的模擬技術來設計自適應和分散式試驗。這種轉變有助於提高患者參與度並降低脫落率。此外，與真實世界資料來源的整合能夠增強臨床洞察力。隨著對個人化醫療需求的不斷成長，預測能力有望顯著推動平台應用和市場成長。

影響測試結果可靠性的演算法偏差

演算法偏差會影響試驗結果的可靠性，對市場信譽構成重大威脅。基於有限或不具代表性的資料集訓練的人工智慧模型可能產生偏差的結果，從而損害試驗的完整性。這導致監管機構、申辦者和患者對人工智慧產生的結論的有效性日益擔憂。此外，人工智慧調查方法缺乏標準化進一步加劇了這些風險。負面結果可能導致更嚴格的審查和核准延遲。因此，解決偏差問題並確保資料多樣性對於維護信任和保障市場的長期發展至關重要。

新冠疫情的影響：

在新冠疫情對傳統臨床試驗營運造成衝擊的同時，也顯著加速了人工智慧驅動的臨床試驗平台的普及應用。封鎖措施和對醫療設施的限制使得分散式和虛擬試驗模式成為必需，也因此更加依賴人工智慧工具。病患招募、監測和資料收集等流程透過數位化解決方案得以簡化。製藥公司迅速採用遠端技術以維持試驗的連續性。這種轉變提高了營運效率，並減少了對實體基礎設施的依賴。因此，疫情起到了催化劑的作用，永久地將臨床試驗調查方法轉變為一個由人工智慧驅動的生態系統。

在預測期內，患者招募平台細分市場預計將成為最大的細分市場。

預計在預測期內，患者招募平台細分市場將佔據最大的市場佔有率。患者入組流程日益複雜是推動此細分市場成長的主要因素。人工智慧工具能夠透過先進的數據分析和電子健康記錄，精準識別合格的受試者，從而顯著降低招募時間和成本。製藥公司優先考慮高效率的入組流程，以避免試驗延誤和經濟損失。此外，更精準的患者配對能夠提高試驗的成功率。因此，對簡化招募流程日益成長的需求正在推動該細分市場佔據領先的市場佔有率。

在預測期內，基於雲端的細分市場預計將呈現最高的複合年成長率。

在預測期內，受對可擴展、靈活解決方案日益成長的需求驅動，雲端解決方案預計將呈現最高的成長率。雲端技術的應用能夠實現即時數據存取、無縫協作和經濟高效的基礎設施管理。企業可以受益於更強大的資料儲存能力和更快的處理速度。此外，雲端平台支援分散式測試和遠端監控，符合不斷發展的行業趨勢。雲端安全技術的持續進步也進一步推動了雲端技術的普及。隨著數位轉型的加速，雲端解決方案可望大幅擴大市場規模。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療保健基礎設施和大型製藥企業的強大影響力。對研發的大量投入，以及對人工智慧技術的早期應用，鞏固了其市場主導地位。有利的法規環境和充足的專業人才資源也進一步推動了市場成長。此外，電子健康記錄的廣泛應用也實現了高效率的數據整合。這些因素共同作用，使北美成為領先的區域市場。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施的快速擴張和臨床試驗活動的日益活躍。中國和印度等新興經濟體正在對數位醫療技術進行大量投資。不斷成長的患者群體和多樣化的資料集為人工智慧的應用提供了強勁的機會。此外，政府的支持性措施和成本優勢也吸引全球製藥公司。這種充滿活力的環境正在加速市場成長，並將亞太地區打造為一個極具潛力的地區。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球人工智慧臨床試驗平台市場：按平台類型分類

  • 病患招募平台
  • 測試設計平台
  • 資料管理平台
  • 臨床分析平台
  • 遠端監控平台
  • 網站管理平台
  • 其他平台類型

第6章 全球人工智慧臨床試驗平台市場：依部署模式分類

  • 基於雲端的
  • 現場
  • 混合
  • SaaS平台
  • 網路為基礎的平台
  • 整合平台

第7章 全球人工智慧臨床試驗平台市場：按技術分類

  • 機器學習
  • 深度學習
  • 自然語言處理
  • 預測分析
  • 巨量資料分析
  • 雲端運算
  • 其他技術

第8章 全球人工智慧臨床試驗平台市場：按應用領域分類

  • 腫瘤臨床試驗
  • 心臟病學領域的臨床試驗
  • 神經病學領域的臨床試驗
  • 感染疾病臨床試驗
  • 罕見疾病臨床試驗
  • 免疫學檢查
  • 其他用途

第9章 全球人工智慧臨床試驗平台市場：按最終用戶分類

  • 製藥公司
  • 生技公司
  • 受託研究機構（CRO）
  • 學術機構
  • 醫院
  • 政府機構
  • 其他最終用戶

第10章 全球人工智慧臨床試驗平台市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Astellas Pharma Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Vericel Corporation
  • Mesoblast Limited
  • Organogenesis Holdings Inc.
  • Bluebird Bio, Inc.
  • Sangamo Therapeutics
  • CRISPR Therapeutics AG
  • Editas Medicine
  • Intellia Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Amgen Inc.
Product Code: SMRC34768

According to Stratistics MRC, the Global AI Clinical Trial Platforms Market is accounted for $3.4 billion in 2026 and is expected to reach $18.8 billion by 2034 growing at a CAGR of 23.8% during the forecast period. AI clinical trial platforms refer to software systems leveraging machine learning, predictive modeling, natural language processing, and real-world data analytics to optimize the design, execution, monitoring, and regulatory submission of pharmaceutical and medical device clinical trials. They automate patient recruitment and eligibility screening, adaptive trial protocol design, safety signal detection, site performance management, and data integrity verification. Key capabilities include electronic data capture integration, decentralized trial support, biomarker-driven patient stratification, and regulatory document generation for IND and NDA submission packages.

Market Dynamics:

Driver:

Faster drug development and recruitment efficiency

Accelerating pharmaceutical innovation cycles, AI clinical trial platforms are enabling faster drug development and recruitment efficiency across global pipelines. Advanced machine learning algorithms streamline patient identification, site selection, and protocol optimization, significantly reducing trial timelines. Sponsors are increasingly leveraging real-time data analytics to enhance decision-making and improve trial success rates. This growing reliance on automation minimizes manual intervention and operational delays. Consequently, the integration of AI is transforming clinical workflows, improving productivity while reducing overall development costs in a competitive landscape.

Restraint:

Data privacy and regulatory compliance issues

Data privacy compliance complexity poses a significant restraint in the AI clinical trial platforms market, driven by stringent regulatory frameworks such as GDPR and HIPAA. Managing sensitive patient data across jurisdictions increases operational burdens and compliance costs. Variability in regional data protection laws complicates cross-border clinical research and data sharing. Additionally, ensuring secure data storage, anonymization, and consent management requires advanced infrastructure, thereby limiting scalability and slowing adoption of AI-driven clinical trial solutions globally.

Opportunity:

Predictive analytics enhancing trial design efficiency

AI clinical trial platforms are unlocking new opportunities in optimizing trial design efficiency. These platforms enable accurate patient stratification, risk assessment, and outcome prediction, enhancing trial precision. Pharmaceutical companies are increasingly adopting AI-driven simulations to design adaptive and decentralized trials. This shift improves patient engagement and reduces dropout rates. Additionally, integration with real-world data sources enhances clinical insights. As demand for personalized medicine rises, predictive capabilities are expected to significantly boost platform adoption and market growth.

Threat:

Algorithm bias impacting trial outcome reliability

Algorithm bias impacting trial outcome reliability poses a critical threat to market credibility. AI models trained on limited or non-representative datasets may produce skewed results, affecting trial integrity. This raises concerns among regulators, sponsors, and patients regarding the validity of AI-driven conclusions. Additionally, lack of standardization in AI methodologies further amplifies these risks. Negative outcomes could lead to increased scrutiny and delayed approvals. Consequently, addressing bias and ensuring data diversity remain essential to sustaining trust and long-term market viability.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated the adoption of AI clinical trial platforms as traditional trial operations faced disruptions. Lockdowns and restricted site access necessitated decentralized and virtual trial models, increasing reliance on AI-driven tools. Patient recruitment, monitoring, and data collection were streamlined through digital solutions. Pharmaceutical companies rapidly embraced remote technologies to maintain trial continuity. This shift enhanced operational efficiency and reduced dependency on physical infrastructure. As a result, the pandemic acted as a catalyst, permanently transforming clinical trial methodologies toward AI-enabled ecosystems.

The patient recruitment platforms segment is expected to be the largest during the forecast period

The patient recruitment platforms segment is expected to account for the largest market share during the forecast period, due to the increasing complexity of patient enrollment processes, the patient recruitment platforms segment is expected to dominate the market. AI-powered tools enable precise identification of eligible participants through advanced data analytics and electronic health records. This significantly reduces recruitment timelines and costs. Pharmaceutical companies prioritize efficient enrollment to avoid trial delays and financial losses. Additionally, improved patient matching enhances trial success rates. Consequently, the growing need for streamlined recruitment processes is reinforcing the segment's leading market share.

The cloud-based segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cloud-based segment is predicted to witness the highest growth rate, driven by the rising demand for scalable and flexible solutions, the cloud-based segment is projected to witness the highest growth rate. Cloud deployment enables real-time data access, seamless collaboration, and cost-effective infrastructure management. Organizations benefit from enhanced data storage capabilities and faster processing speeds. Additionally, cloud platforms support decentralized trials and remote monitoring, aligning with evolving industry trends. Continuous advancements in cloud security further strengthen adoption. As digital transformation accelerates, cloud-based solutions are expected to drive significant market expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to its advanced healthcare infrastructure and strong presence of leading pharmaceutical companies. High investment in research and development, coupled with early adoption of AI technologies, supports market dominance. Favorable regulatory frameworks and availability of skilled professionals further enhance growth. Additionally, widespread use of electronic health records enables efficient data integration. These factors collectively position North America as the leading regional market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly expanding healthcare infrastructure and increasing clinical trial activities. Emerging economies such as China and India are investing heavily in digital health technologies. Growing patient populations and diverse datasets provide strong opportunities for AI adoption. Additionally, supportive government initiatives and cost advantages attract global pharmaceutical companies. This dynamic environment is accelerating market growth, positioning Asia Pacific as a high-potential region.

Key players in the market

Some of the key players in AI Clinical Trial Platforms Market include Astellas Pharma Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Johnson & Johnson, Vericel Corporation, Mesoblast Limited, Organogenesis Holdings Inc., Bluebird Bio, Inc., Sangamo Therapeutics, CRISPR Therapeutics AG, Editas Medicine, Intellia Therapeutics, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences, Inc., and Amgen Inc..

Key Developments:

In March 2026, Novartis AG announced implementation of an AI clinical trial monitoring platform across 150 active studies reducing on-site monitoring visits through risk-based analytics.

In February 2026, Takeda Pharmaceutical Company Limited expanded its AI clinical operations platform partnership to optimize adaptive trial design and real-world evidence integration across rare disease programs.

In January 2026, Pfizer Inc. deployed an AI-powered patient recruitment and eligibility screening platform across its global Phase III oncology trial portfolio to accelerate enrollment timelines.

In November 2025, Roche Holding AG launched a decentralized trial AI management platform enabling remote patient data collection for its neurology and oncology Phase II and III programs.

Platform Types Covered:

  • Carbon Management Tools
  • Energy Optimization Tools
  • Waste Management Tools
  • Supply Chain Sustainability Tools
  • ESG Analytics Platforms
  • Climate Risk Modeling Tools
  • Other Tool Types

Deployment Modes Covered:

  • Cloud-based
  • On-premise
  • Hybrid
  • SaaS Platforms
  • Web-based Platforms
  • Integrated Platforms

Technologies Covered:

  • Machine Learning
  • Deep Learning
  • Natural Language Processing
  • Predictive Analytics
  • Big Data Analytics
  • Cloud Computing
  • Other Technologies

Applications Covered:

  • Oncology Trials
  • Cardiology Trials
  • Neurology Trials
  • Infectious Disease Trials
  • Rare Disease Trials
  • Immunology Trials
  • Other Applications

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Contract Research Organizations (CROs)
  • Academic Institutes
  • Hospitals
  • Government Organizations
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI Clinical Trial Platforms Market, By Platform Type

  • 5.1 Patient Recruitment Platforms
  • 5.2 Trial Design Platforms
  • 5.3 Data Management Platforms
  • 5.4 Clinical Analytics Platforms
  • 5.5 Remote Monitoring Platforms
  • 5.6 Site Management Platforms
  • 5.7 Other Platform Types

6 Global AI Clinical Trial Platforms Market, By Deployment Mode

  • 6.1 Cloud-based
  • 6.2 On-premise
  • 6.3 Hybrid
  • 7.4 SaaS Platforms
  • 7.5 Web-based Platforms
  • 7.6 Integrated Platforms

7 Global AI Clinical Trial Platforms Market, By Technology

  • 7.1 Machine Learning
  • 7.2 Deep Learning
  • 7.3 Natural Language Processing
  • 7.4 Predictive Analytics
  • 7.5 Big Data Analytics
  • 7.6 Cloud Computing
  • 7.7 Other Technologies

8 Global AI Clinical Trial Platforms Market, By Application

  • 8.1 Oncology Trials
  • 8.2 Cardiology Trials
  • 8.3 Neurology Trials
  • 8.4 Infectious Disease Trials
  • 8.5 Rare Disease Trials
  • 8.6 Immunology Trials
  • 8.7 Other Applications

9 Global AI Clinical Trial Platforms Market, By End User

  • 9.1 Pharmaceutical Companies
  • 9.2 Biotechnology Firms
  • 9.3 Contract Research Organizations (CROs)
  • 9.4 Academic Institutes
  • 9.5 Hospitals
  • 9.6 Government Organizations
  • 9.7 Other End Users

10 Global AI Clinical Trial Platforms Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Astellas Pharma Inc.
  • 13.2 Novartis AG
  • 13.3 Pfizer Inc.
  • 13.4 Roche Holding AG
  • 13.5 Johnson & Johnson
  • 13.6 Vericel Corporation
  • 13.7 Mesoblast Limited
  • 13.8 Organogenesis Holdings Inc.
  • 13.9 Bluebird Bio, Inc.
  • 13.10 Sangamo Therapeutics
  • 13.11 CRISPR Therapeutics AG
  • 13.12 Editas Medicine
  • 13.13 Intellia Therapeutics
  • 13.14 Takeda Pharmaceutical Company Limited
  • 13.15 Bristol-Myers Squibb Company
  • 13.16 AbbVie Inc.
  • 13.17 Gilead Sciences, Inc.
  • 13.18 Amgen Inc.

List of Tables

  • Table 1 Global AI Clinical Trial Platforms Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global AI Clinical Trial Platforms Market Outlook, By Platform Type (2023-2034)($MN)
  • Table 3 Global AI Clinical Trial Platforms Market Outlook, By Patient Recruitment Platforms (2023-2034)($MN)
  • Table 4 Global AI Clinical Trial Platforms Market Outlook, By Trial Design Platforms (2023-2034)($MN)
  • Table 5 Global AI Clinical Trial Platforms Market Outlook, By Data Management Platforms (2023-2034)($MN)
  • Table 6 Global AI Clinical Trial Platforms Market Outlook, By Clinical Analytics Platforms (2023-2034)($MN)
  • Table 7 Global AI Clinical Trial Platforms Market Outlook, By Remote Monitoring Platforms (2023-2034)($MN)
  • Table 8 Global AI Clinical Trial Platforms Market Outlook, By Site Management Platforms (2023-2034)($MN)
  • Table 9 Global AI Clinical Trial Platforms Market Outlook, By Other Platform Types (2023-2034)($MN)
  • Table 10 Global AI Clinical Trial Platforms Market Outlook, By Deployment Mode (2023-2034)($MN)
  • Table 11 Global AI Clinical Trial Platforms Market Outlook, By Cloud-based (2023-2034)($MN)
  • Table 12 Global AI Clinical Trial Platforms Market Outlook, By On-premise (2023-2034)($MN)
  • Table 13 Global AI Clinical Trial Platforms Market Outlook, By Hybrid (2023-2034)($MN)
  • Table 14 Global AI Clinical Trial Platforms Market Outlook, By SaaS Platforms (2023-2034)($MN)
  • Table 15 Global AI Clinical Trial Platforms Market Outlook, By Web-based Platforms (2023-2034)($MN)
  • Table 16 Global AI Clinical Trial Platforms Market Outlook, By Integrated Platforms (2023-2034)($MN)
  • Table 17 Global AI Clinical Trial Platforms Market Outlook, By Technology (2023-2034)($MN)
  • Table 18 Global AI Clinical Trial Platforms Market Outlook, By Machine Learning (2023-2034)($MN)
  • Table 19 Global AI Clinical Trial Platforms Market Outlook, By Deep Learning (2023-2034)($MN)
  • Table 20 Global AI Clinical Trial Platforms Market Outlook, By Natural Language Processing (2023-2034)($MN)
  • Table 21 Global AI Clinical Trial Platforms Market Outlook, By Predictive Analytics (2023-2034)($MN)
  • Table 22 Global AI Clinical Trial Platforms Market Outlook, By Big Data Analytics (2023-2034)($MN)
  • Table 23 Global AI Clinical Trial Platforms Market Outlook, By Cloud Computing (2023-2034)($MN)
  • Table 24 Global AI Clinical Trial Platforms Market Outlook, By Other Technologies (2023-2034)($MN)
  • Table 25 Global AI Clinical Trial Platforms Market Outlook, By Application (2023-2034)($MN)
  • Table 26 Global AI Clinical Trial Platforms Market Outlook, By Oncology Trials (2023-2034)($MN)
  • Table 27 Global AI Clinical Trial Platforms Market Outlook, By Cardiology Trials (2023-2034)($MN)
  • Table 28 Global AI Clinical Trial Platforms Market Outlook, By Neurology Trials (2023-2034)($MN)
  • Table 29 Global AI Clinical Trial Platforms Market Outlook, By Infectious Disease Trials (2023-2034)($MN)
  • Table 30 Global AI Clinical Trial Platforms Market Outlook, By Rare Disease Trials (2023-2034)($MN)
  • Table 31 Global AI Clinical Trial Platforms Market Outlook, By Immunology Trials (2023-2034)($MN)
  • Table 32 Global AI Clinical Trial Platforms Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 33 Global AI Clinical Trial Platforms Market Outlook, By End User (2023-2034)($MN)
  • Table 34 Global AI Clinical Trial Platforms Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 35 Global AI Clinical Trial Platforms Market Outlook, By Biotechnology Firms (2023-2034)($MN)
  • Table 36 Global AI Clinical Trial Platforms Market Outlook, By Contract Research Organizations (CROs) (2023-2034)($MN)
  • Table 37 Global AI Clinical Trial Platforms Market Outlook, By Academic Institutes (2023-2034)($MN)
  • Table 38 Global AI Clinical Trial Platforms Market Outlook, By Hospitals (2023-2034)($MN)
  • Table 39 Global AI Clinical Trial Platforms Market Outlook, By Government Organizations (2023-2034)($MN)
  • Table 40 Global AI Clinical Trial Platforms Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.